Point-of-care reversal treatment in phenprocoumon-related intracerebral hemorrhage

Ann Neurol. 2010 Jun;67(6):788-93. doi: 10.1002/ana.21965.

Abstract

Objective: Rapid reversal of the anticoagulatory effect of vitamin K antagonists represents the primary emergency treatment for oral anticoagulant-related intracerebral hemorrhage (OAC-ICH). Predicting the amount of prothrombin complex concentrate (PCC) needed to reverse OAC in individual patients is difficult, and repeated international normalized ratio (INR) measurements in central laboratories (CLs) are time-consuming. Accuracy and effectiveness of point-of-care INR coagulometers (POCs) for INR reversal in OAC-ICH have not been evaluated.

Methods: In phase 1, the agreement of emergency POC and CL INR measurements was determined. In phase 2, stepwise OAC reversal was performed with PCC using a predetermined dosing schedule. Concordance of POC and CL INR measurements during reversal and time gain due to POC were determined.

Results: In phase 1 (n = 165), Bland-Altman analysis showed close agreement between POCs and CLs (mean INR deviation 0.04). In phase 2 (n = 26), POCs caused a median initial net time gain of 24 minutes for the start of treatment with PCC. Median time for POC-documented complete OAC reversal was 28 minutes, compared with 120 minutes for CLs. Bland-Altman analysis between POCs and CLs revealed a mean INR deviation of 0.13 during stepwise PCC administration. POCs tended to slightly overestimate the INR, especially at higher INR levels. Remarkably, POC-guided reversal led to a median reduction of 30.5% of PCC dose compared with the a priori dose calculation. Hematomas enlarged in 20% of patients.

Interpretation: POC INR monitoring is a fast, effective, and economic means of PCC dose-titration in OAC-ICH. Larger studies examining the clinical efficacy of this procedure are warranted.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anticoagulants / metabolism
  • Anticoagulants / therapeutic use*
  • Blood Coagulation Factors / metabolism
  • Cerebral Hemorrhage / drug therapy*
  • Cerebral Hemorrhage / metabolism*
  • Cerebral Hemorrhage / pathology
  • Female
  • Follow-Up Studies
  • Hematoma / drug therapy
  • Hematoma / etiology
  • Hematoma / pathology
  • Humans
  • International Normalized Ratio / methods
  • Male
  • Phenprocoumon / metabolism
  • Phenprocoumon / therapeutic use*
  • Prospective Studies
  • Time Factors
  • Treatment Outcome

Substances

  • Anticoagulants
  • Blood Coagulation Factors
  • prothrombin complex concentrates
  • Phenprocoumon